OMA Guidelines Bundle

Obesity-Related Diseases 2026

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1544298

Contents of this Issue

Navigation

Page 36 of 45

37 Obesity and Diabetes Medication Management of Type 2 Diabetes   ➤ Prioritize the use of glucose-lowering medications with proven weight-loss benefits.   ➤ The most effective medications for managing diabetes and obesity are the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist tirzepatide, as well as the subcutaneous GLP-1 RA semaglutide.   ➤ Other subcutaneous GLP-1 RAs are effective in controlling blood glucose levels and assisting with weight loss, but are less effective than tirzepatide and semaglutide.   ➤ SGLT2 inhibitors and metformin can also induce modest weight loss.   ➤ For individuals treated with SGLT2 inhibitors, ketogenic diets may increase the risk of ketoacidosis.   ➤ Medications that predispose to hypoglycemia should be titrated downward or discontinued with weight loss.   ➤ Consider referral to adult endocrinology if diabetes is not well controlled despite titration of medications.   ➤ Consider referral to pediatric endocrinology for the treatment of type 2 diabetes in children. Role and Benefits of Metabolic and Bariatric Surgery   ➤ Consider metabolic and bariatric surgery for people with diabetes mellitus and obesity (BMI >30 kg/m² or ≥27 kg/m² in Asian individuals).   ➤ Benefits include significant long-term weight loss, superior glycemic control, reduced cardiovascular disease, lower all-cause mortality, and improved quality of life. Diabetes Remission   ➤ Defined as hemoglobin A1c <6.5% maintained for at least three months following discontinuation of all glucose-lowering medications.   ➤ Diabetes remission following bariatric surgery has been reported as 38% at 3 years and 13% at 12 years.

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity-Related Diseases 2026